Literature DB >> 2144018

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.

W J Hrushesky1, R von Roemeling, R M Lanning, J T Rabatin.   

Abstract

Sixty-eight unselected patients with progressive metastatic renal cell carcinoma (RCC) were treated between March 1985 and November 1988 with continuous infusion floxuridine (FUDR). Thirty-seven percent of these patients had previously received and failed systemic treatment. Using implantable pumps for automatic drug delivery, FUDR was continuously infused for 14 days at monthly intervals. The starting dose was 0.15 mg/kg/d (intravenous [IV]; n = 61) or 0.25 mg/kg/d (intraarterial [IA]; n = 7); IV doses were increased or decreased in increments of 0.025 mg/kg/d as permitted by toxicity. Diarrhea (with or without mild abdominal cramping) and nausea/vomiting limited the FUDR IV infusion, and hepatic function abnormalities limited FUDR IA infusion. The use of a circadian-modified infusion schedule permitted high FUDR doses to be safely given as compared with a constant rate infusion schedule. Of 63 patients assessable for response, 56 received systemic FUDR infusion. Four complete responses (CRs; 7.1%); and seven partial responses (PRs; 12.5%) were observed (objective response rate, CR plus PR, 19.6 +/- 5.1% [95% confidence limits] ). The median objective response duration was 10.8 months (range, 1 to 18 months; mean, 9.4 +/- 1.6). Four additional patients had minor tumor responses (MRs; 7.1%). In a subgroup of seven assessable patients receiving hepatic arterial FUDR, we observed one CR and three PRs (57.2 +/- 42.8%). Overall, objective response (CR plus PR) was seen in a quarter of assessable patients treated, 15 of 63, while only 15 of the 63 assessable patients (25.4%) have had objective tumor progression. The median follow-up time for all 68 patients was 28 months (range, 1 to 42), and their median survival duration is 15 months (range, 3 to 37 months). Continuous infusion FUDR is an effective outpatient treatment for progressive metastatic RCC, producing durable tumor response and causing little toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144018     DOI: 10.1200/JCO.1990.8.9.1504

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  14 in total

Review 1.  Continuous hepatic artery infusion (CHAI) as treatment of liver metastases. Are the complications worth it?

Authors:  M M Kemeny
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

Review 2.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

Review 3.  Chemotherapy in metastatic renal cell cancer.

Authors:  Wolfgang Lilleby; Sophie D Fosså
Journal:  World J Urol       Date:  2005-02-22       Impact factor: 4.226

4.  Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.

Authors:  Keith M Skubitz
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

Review 5.  Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.

Authors:  Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen
Journal:  Support Care Cancer       Date:  2012-11-10       Impact factor: 3.603

Review 6.  WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.

Authors:  Zsofia Kiss; Paramita M Ghosh
Journal:  Endocr Relat Cancer       Date:  2016-09-22       Impact factor: 5.678

7.  The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy.

Authors:  R Zhang; Z Lu; C R Diasio; T Liu; S J Soong
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.

Authors:  B R Murphy; S M Rynard; L H Einhorn; P J Loehrer
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

Review 9.  Complications of hepatic artery infusion: a review of 4580 reported cases.

Authors:  K T Barnett; M P Malafa
Journal:  Int J Gastrointest Cancer       Date:  2001

10.  Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.

Authors:  W M Stadler; N J Vogelzang; E E Vokes; J Charette; G Whitman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.